{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:54:01Z","timestamp":1792839241617,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jhep.2016.10.013","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T04:01:38Z","timestamp":1476936098000},"page":"645-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Battlefield against hepatitis B infection and HCC in Africa"],"prefix":"10.1016","volume":"66","author":[{"given":"Maud","family":"Lemoine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Thursz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.10.013_b0005","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.10.013_b0010","unstructured":"IARC. http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx, Last access 23 January 2016, 2012."},{"key":"10.1016\/j.jhep.2016.10.013_b0015","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1002\/cncr.27410","article-title":"Cancer burden in Africa and opportunities for prevention","volume":"118","author":"Jemal","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2016.10.013_b0020","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1470-2045(08)70175-X","article-title":"Part I: Cancer in Indigenous Africans\u2013burden, distribution, and trends","volume":"9","author":"Parkin","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2016.10.013_b0025","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ijc.27646","article-title":"Evaluation of data quality at the Gambia national cancer registry","volume":"132","author":"Shimakawa","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2016.10.013_b0030","unstructured":"www.prolifica.org.uk NCT02129829 clinical trials org Last accessed 15 August 2016."},{"key":"10.1016\/j.jhep.2016.10.013_b0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/apt.13484","article-title":"Hepatitis E virus infection and acute-on-chronic liver failure in West Africa: a case-control study from The Gambia","volume":"43","author":"Shimakawa","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.10.013_b0040","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","article-title":"The burden of liver disease in Europe: a review of available epidemiological data","volume":"58","author":"Blachier","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.10.013_b0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/hep.20027","article-title":"The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa","volume":"39","author":"Kirk","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.013_b0050","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/ajg.2015.289","article-title":"Hepatocellular carcinoma occurs at an earlier age in Africans, particularly in association with chronic hepatitis B","volume":"110","author":"Yang","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.10.013_b0055","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.27969","article-title":"World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma","volume":"62","author":"de Martel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.013_b0060","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJM198110293051807","article-title":"Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens","volume":"305","author":"Shafritz","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.10.013_b0065","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1440-1746.2008.05481.x","article-title":"Occult hepatitis B virus infection in Southern African blacks with hepatocellular carcinoma","volume":"23","author":"Kew","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.10.013_b0070","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/liv.12209","article-title":"Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases","volume":"33","author":"Shaker","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.10.013_b0075","doi-asserted-by":"crossref","first-page":"379","DOI":"10.11604\/pamj.2014.19.379.4143","article-title":"Epidemiology of hepatitis C: related hepatocellular carcinoma in Cameroon","volume":"19","author":"Andoulo","year":"2014","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.jhep.2016.10.013_b0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1478-3231.2011.02481.x","article-title":"Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis","volume":"32","author":"Shi","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.10.013_b0085","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.10.013_b0090","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/infdis\/161.6.1112","article-title":"The pattern of childhood hepatitis B infection in two Gambian villages","volume":"161","author":"Whittle","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2016.10.013_b0095","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1016\/S2214-109X(16)30130-9","article-title":"Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study","volume":"4","author":"Lemoine","year":"2016","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jhep.2016.10.013_b0100","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1186\/1471-2458-14-532","article-title":"The association between maternal hepatitis B e antigen status, as a proxy for perinatal transmission, and the risk of hepatitis B e antigenaemia in Gambian children","volume":"14","author":"Shimakawa","year":"2014","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jhep.2016.10.013_b0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/oxfordjournals.aje.a113406","article-title":"Hepatitis B infection in households of chronic carriers of hepatitis B surface antigen: factors associated with prevalence of infection","volume":"116","author":"Bernier","year":"1982","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jhep.2016.10.013_b0110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/ije\/dyg039","article-title":"Mortality of hepatitis B surface antigen-positive blood donors in England and Wales","volume":"32","author":"Crook","year":"2003","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jhep.2016.10.013_b0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.10.013_b0120","first-page":"559","article-title":"Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma","volume":"7","author":"Evans","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jhep.2016.10.013_b0125","article-title":"Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia","author":"Shimakawa","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.10.013_b0130","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.10.013_b0135","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.10.013_b0140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jmv.10559","article-title":"Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers","volume":"72","author":"Tang","year":"2004","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2016.10.013_b0145","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jmv.20311","article-title":"Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-saharan Africans","volume":"75","author":"Kew","year":"2005","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2016.10.013_b0150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijid.2014.07.002","article-title":"Genotyping and virological characteristics of hepatitis B virus in HIV-infected individuals in Sudan","volume":"29","author":"Yousif","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jhep.2016.10.013_b0155","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/liv.12814","article-title":"Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in The Gambia","volume":"35","author":"Shimakawa","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.10.013_b0160","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ejca.2012.02.009","article-title":"Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis","volume":"48","author":"Liu","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2016.10.013_b0165","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/854530","article-title":"Role of sex hormones in the development and progression of hepatitis B virus-associated hepatocellular carcinoma","volume":"2015","author":"Montella","year":"2015","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.jhep.2016.10.013_b0170","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0140-6736(14)60892-8","article-title":"Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults","volume":"384","author":"Bhaskaran","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.10.013_b0175","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2008.03.073","article-title":"Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B\/C infection: a follow-up study in Taiwan","volume":"135","author":"Chen","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.10.013_b0180","unstructured":"WHO. http:\/\/appswhoint\/iris\/bitstream\/10665\/112736\/1\/9789240692763_engpdf, Last access 28th January, 2016."},{"key":"10.1016\/j.jhep.2016.10.013_b0185","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0035-9203(93)90154-I","article-title":"Cost-effectiveness of hepatitis B vaccine in The Gambia","volume":"87","author":"Hall","year":"1993","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.jhep.2016.10.013_b0190","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/hec.625","article-title":"Economic evaluations of hepatitis B immunization: a global review of recent studies (1994\u20132000)","volume":"10","author":"Beutels","year":"2001","journal-title":"Health Econ"},{"key":"10.1016\/j.jhep.2016.10.013_b0195","unstructured":"WHO. http:\/\/www.who.int\/immunization\/monitoring_surveillance\/Global_Immunization_Data.pdf?ua=1, Last accessed 1st February 2016, 2015."},{"key":"10.1016\/j.jhep.2016.10.013_b0200","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/jama.1987.03390190075023","article-title":"A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers","volume":"257","author":"Chen","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.10.013_b0205","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/jama.1988.03410150079034","article-title":"Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers","volume":"260","author":"Hsu","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.10.013_b0210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1086\/314585","article-title":"Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization","volume":"179","author":"Hsu","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2016.10.013_b0215","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1086\/315259","article-title":"Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program","volume":"181","author":"Harpaz","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2016.10.013_b0220","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1016\/j.vaccine.2009.08.048","article-title":"Epidemiological serosurvey of hepatitis B in China\u2013declining HBV prevalence due to hepatitis B vaccination","volume":"27","author":"Liang","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2016.10.013_b0225","first-page":"5782","article-title":"The Gambia Hepatitis Study Group","volume":"47","author":"The Gambia Hepatitis Intervention Study","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2016.10.013_b0230","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2334-14-7","article-title":"Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986\u201390) and in the nationwide immunisation program","volume":"14","author":"Peto","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhep.2016.10.013_b0235","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/INF.0b013e31829be401","article-title":"Hepatitis B virus exposure during childhood in Cameroon, Central African Republic and Senegal after the integration of HBV vaccine in the expanded program on immunization","volume":"32","author":"Rey-Cuille","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jhep.2016.10.013_b0240","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group","volume":"336","author":"Chang","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.10.013_b0245","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.2013.276701","article-title":"Thirty-year outcomes of the national hepatitis B immunization program in Taiwan","volume":"310","author":"Chiang","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.10.013_b0250","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/hep.27048","article-title":"Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccinees","volume":"60","author":"Chien","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.013_b0255","first-page":"507","article-title":"Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program","volume":"9","author":"Wichajarn","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jhep.2016.10.013_b0260","doi-asserted-by":"crossref","first-page":"J66","DOI":"10.1016\/j.vaccine.2013.03.043","article-title":"The impact of hepatitis B vaccine in China and in the China GAVI Project","volume":"31","author":"Hadler","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2016.10.013_b0265","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1098\/rspb.1993.0102","article-title":"The influence of age on the development of the hepatitis B carrier state","volume":"253","author":"Edmunds","year":"1993","journal-title":"Proc Biol Sci"},{"key":"10.1016\/j.jhep.2016.10.013_b0270","first-page":"405","article-title":"Hepatitis B vaccines. WHO position paper","volume":"84","author":"WHO","year":"2009","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.jhep.2016.10.013_b0275","unstructured":"GAVI. Hepatitis B vaccine at birth GAVI responds to MSF, 2014. Available at: http:\/\/www.gavi.org\/Library\/News\/Statements\/2014\/Hepatitis-B-vaccine-at-birth-GAVI-responds-to-MSF\/, 2014."},{"key":"10.1016\/j.jhep.2016.10.013_b0280","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.vaccine.2008.03.018","article-title":"A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Cote d'Ivoire","volume":"26","author":"Ekra","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2016.10.013_b0285","unstructured":"WHO. World Health Organization. Guidelines for the Prevention, Care and Treatment of Persons with chronic Hepatitis B infection. http:\/\/whoint\/hiv\/pub\/hepatitis\/hepatitis-b-guidelines\/en\/2015; March, Last accessed July 2016."},{"key":"10.1016\/j.jhep.2016.10.013_b0290","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hep.28302","article-title":"Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis","volume":"63","author":"Brown","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.013_b0295","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","author":"Marcellin","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.10.013_b0300","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B \u2013 a nationwide cohort study","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.10.013_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.10.013_b0310","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jhep.2009.04.013","article-title":"Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B","volume":"51","author":"Buti","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.10.013_b0315","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jhep.2014.10.008","article-title":"Reducing the neglected burden of viral hepatitis in Africa: Strategies for a global approach","volume":"62","author":"Lemoine","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.10.013_b0320","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2214-109X(16)30101-2","article-title":"Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis","volume":"4","author":"Nayagam","year":"2016","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jhep.2016.10.013_b0325","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/cid\/ciu210","article-title":"Rapid detection of hepatitis B virus in blood plasma by a specific and sensitive loop-mediated isothermal amplification assay","volume":"59","author":"Nyan","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.10.013_b0330","article-title":"The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa","author":"Lemoine","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.10.013_b0335","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1136\/gutjnl-2016-312326","article-title":"Diagnostic accuracy of the \u03b3-glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4","volume":"65","author":"Shimakawa","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.10.013_b0340","article-title":"The gamma-glutamyl transpeptidase-to-platelet ratio as a predictor of liver fibrosis in patients co-infected with HBV and HIV","author":"Boyd","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.10.013_b0345","author":"Stockdale","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.10.013_b0350","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/MCG.0b013e3182755c13","article-title":"Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months: a 15-year prospective study","volume":"47","author":"Han","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2016.10.013_b0355","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep.24545","article-title":"Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities","volume":"54","author":"Trinchet","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.013_b0360","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-154-2-201101180-00006","article-title":"Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States","volume":"154","author":"Davila","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.10.013_b0365","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1053\/j.gastro.2004.09.023","article-title":"Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma","volume":"127","author":"Daniele","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.10.013_b0370","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.27264","article-title":"Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma (HCC) in West Africans","volume":"60","author":"Ladep","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.10.013_b0375","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0269216314547103","article-title":"The prevalence and burden of symptoms in patients with chronic liver diseases in The Gambia, West Africa","volume":"29","author":"Shimakawa","year":"2015","journal-title":"Palliat Med"},{"key":"10.1016\/j.jhep.2016.10.013_b0380","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0140-6736(05)67094-8","article-title":"Palliative care in sub-Saharan Africa","volume":"366","author":"Colebunders","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.10.013_b0385","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3748\/wjg.v19.i10.1508","article-title":"Aflatoxins, hepatocellular carcinoma and public health","volume":"19","author":"Magnussen","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.10.013_b0390","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1383-5742(00)00027-2","article-title":"Primary prevention of hepatocellular carcinoma in developing countries","volume":"462","author":"Wild","year":"2000","journal-title":"Mutat Res"},{"key":"10.1016\/j.jhep.2016.10.013_b0395","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","article-title":"Global control of hepatitis B virus infection","volume":"2","author":"Kao","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2016.10.013_b0400","unstructured":"World Health Organization (WHO). http:\/\/www.worldhepatitissummit.org\/docs\/default-source\/default-document-library\/2015\/resources\/towards-elimination-dr-gottfried-hirnschall.pdf?sfvrsn=6; 2016 June, Last accessed 23th Nov 2016."}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816305785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816305785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T20:02:44Z","timestamp":1657483364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816305785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0168827816305785"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.10.013","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Battlefield against hepatitis B infection and HCC in Africa","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}